Search
Metocurine iodide
go.drugbank.com/drugs/DB00416ApprovedWithdrawnMetocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. … It is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine
Chlorthalidone
go.drugbank.com/drugs/DB00310ApprovedInvestigationalIn addition to its antihypertensive effects, chlorthalidone has also been shown to decrease platelet aggregation and vascular permeability, as well as promote angiogenesis in vitro, which is thought to … Chlorthalidone is a thiazide-like diuretic used for the treatment of hypertension and for management of edema caused by conditions such as heart failure or renal impairment.
Mixtures: ATENOLOL CO RATIO 100/25MGRevefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigationalRevefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA). … [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]
Atidarsagene autotemcel
go.drugbank.com/drugs/DB17538ApprovedInvestigational[L45191] Libmeldy was granted orphan designation by the EMA in April 2007, and was issued a marketing authorization in the EU in December 2020 for the treatment of certain manifestations of metachromatic
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalOsimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. … Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells.
Margetuximab
go.drugbank.com/drugs/DB14967ApprovedInvestigationalOf the various subtypes of breast cancer, HER2-positive breast cancer is characterized by _ERBB2_ overexpression, a higher grade, a more aggressive phenotype, and a worse prognosis compared to HER2-negative … [A225751] The introduction of [trastuzumab] improved patient outcomes in HER2-positive breast cancer, but notably depended substantially on polymorphisms in the FcγRIIIA/CD16A receptor, whereby low affinity
Selenious acid
go.drugbank.com/drugs/DB11127ApprovedSelenium (Se) has been demonstrated to prevent cancer in numerous animal models when administered selenium at levels exceeding the nutritional requirements. … The reports from such studies have heightened the interest in additional human selenium supplementation studies to validate the results in larger populations [L1918].
Mixtures: Micro+ Te PediatricIvacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigationalIt is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012[L768], and by Health Canada in late 2012. … [A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage
Voxelotor
go.drugbank.com/drugs/DB14975Approved[L10403] It was developed by Global Blood Therapeutics, Inc. … to 20 million others worldwide.
Viltolarsen
go.drugbank.com/drugs/DB15005ApprovedInvestigationalDuchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function … Viltolarsen was developed by Nippon Shinyaku Co LTD and is being marketed under the name VILTEPSO™.[L15526]